Abstract: Myocardial responses to acute ischemia/reperfusion and to chronic ischemic conditions have been studied extensively at all levels of organization. These include subcellular (eg, mitochondria in vitro); intact, large animal models (eg, swine with chronic coronary stenosis); as well as human subjects. Investigations in humans have used positron emission tomographic metabolic and myocardial blood flow measurements, assessment of gene expression and anatomic description of myocardium obtained at the time of coronary artery revascularization, ventricular assist device placement, or heart transplantation. A multitude of genetic, molecular, and metabolic pathways have been identified, which may promote either myocyte survival or death or, most interestingly, both. Many of these potential mediators in both acute ischemia/reperfusion and adaptations to chronic ischemic conditions involve the mitochondria, which play a central role in cellular energy production and homeostasis. The present review is focused on operative survival mechanisms and potential myocardial viability molecular imaging targets in acute and chronic ischemia, especially those which impact mitochondrial function. (Circ Res.
A major challenge for present cardiovascular imaging is to identify better ways to assess viable (but inadequately perfused) myocardium and thus optimize selection of patients for coronary revascularization. Current myocardial viability imaging techniques interrogate structural and functional integrity of the cardiac myocyte and its intracellular processes. 1, 2 Dobutamine echocardiography assesses regional left ventricular contractile reserve. 3 Delayed gadolinium contrast enhancement with cardiac magnetic resonance (CMR) identifies scarred myocardium. [4] [5] [6] Single photon emission tomography (SPECT) and positron emission tomography (PET) examine myocardial perfusion, 7, 8 sarcolemma, 9,10 mitochondrial 11 inner membrane integrity, intracellular fatty acid, 12 and glucose metabolism. 1, [13] [14] [15] [16] [17] PET myocardial 18 fluorodeoxyglucose (FDG) imaging combined with rest myocardial blood flow (MBF) measurement 1, 13, 15, 16, 18 and CMR assessment of transmural extent of delayed gadolinium enhancement [4] [5] [6] 19, 20 are the current imaging modalities of choice (neither was used in the nonrandomized STICH viability substudy [Surgical Treatment for Ischemic Heart Failure; ClinicalTrials.gov identifier: NCT00023595] 21 ). Selection of modality typically depends on some combination of clinical circumstances, local expertise, and resource availability. However, both methods have their limitations. Thus, positive and negative predictive value for myocardial viability, defined as recovery of segmental contractile function, has been reported for PET FDG as 73% (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) and 90% (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) , respectively (mean [95% confidence interval]). 22 Comparable statistics for contrast-enhanced CMR are similar, 73% (57-89) and 93% (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) , respectively (mean [95% confidence interval]). 22 Accordingly, efforts at improvement, especially in the positive predictive accuracy metric (25% false-positive rate), are ongoing 5 and clearly needed. The clinician considering coronary revascularization for a patient will wish to know who is most likely to benefit from the procedure (ie, has substantial residual viable myocardium), and thus, a test with high positive predictive accuracy is required. A test with high negative predictive accuracy (eg, PET 18 FDG, CMR delayed gadolinium enhancement) tells the clinician who will not benefit from revascularization but does not necessarily identify who will. Ultimately, such improvements are most likely to come from a better understanding of pathophysiological mechanisms operative in myocardial survival under conditions of acute and chronic ischemia. Technological advances, such as PET/computed tomography and PET/MR, likely will play an important role as well. Accordingly, the present review will provide essential biological information concerning myocardial survival mechanisms, describe ways in which current myocardial imaging modalities exploit some of these mechanisms, and suggest potential future targets for molecular imaging assessment of myocardial viability.
Identification of Potential Molecular Imaging Targets Related to Myocardial Viability Mitochondrial Membrane Potential
The myocyte mitochondrial population ultimately bears the brunt of a multitude of signals generated by the ischemia/reperfusion process ( Figure 1 ). An important concept, pointed out by others, is the notion that a given signal may be either protective or harmful depending on dose. [23] [24] [25] [26] Hence, ischemia-driven intracellular acidosis at more moderate levels will help stabilize the mitochondrial membrane permeability transition pore (mPTP), 24, 26 which is vital for the maintenance of the mitochondrial membrane potential (∆ψ ) and thus ATP production. More profound acidosis results in opening mPTP, which in turn causes collapse of ∆ψ followed by influx of sodium, swelling of the matrix, and ultimately rupture of the outer membrane. 24, 26 Release of cytochrome c from the outer surface of the inner mitochondrial membrane (Figure 2 ) into the cell cytoplasm may activate lysosomal caspases and initiate apoptosis. If the insult is severe enough, additional lysosomal contents are released, the cell membrane undergoes permeabilization, and necrotic cell death ensues. Release of cell contents to the interstitial space follows 24, 26 and provokes an intense inflammatory response, which initiates a chain reaction of necrosis of myocytes in the vicinity of the initial insult.
It is well known that the sequence of events outlined above is modifiable to a greater or lesser extent by extensively investigated interventions of ischemic preconditioning, intraconditioning, postconditioning, and remote conditioning either preceding or after onset of ischemia and subsequent reperfusion. 23, 24, [26] [27] [28] [29] Nitric oxide, protein kinases, and mitochondria each play important roles in all forms of conditioning 23 and so directly or indirectly are potentially useful targets for molecular imaging. Moreover, because so much of the signaling, both immediate and delayed (protein expression/gene regulation) converges on the mitochondria, that organelle represents an excellent target to probe.
It is important to recognize that each cardiomyocyte contains a large and variable number of mitochondria (mitochondrial fission and fusion is an ongoing process) not all of which have the same ∆ψ. 30 Accordingly, inferences drawn from in vivo imaging regarding ∆ψ will reflect the mean of the population in the field of view and will be limited by the spatial resolution of the modality used. In the case of PET, typical reconstructed image resolution for a modern scanner operating in 2-dimensional mode is generally given as ≈5 mm full width half maximum 31 although positron energy plays an important role. It will be best with a low energy emitter such as 18 F (0.6 mm, mean range in water) and worst with a high energy one, 82 Rb (4.2 mm), with 11 C, 13 N, and 15 O intermediate (1.0, 1.3, and 2.0 mm, respectively). 32 The reconstructed image in each case, however, for technical reasons will have lesser spatial resolution (full width half maximum) than that of the intrinsic range in tissue of the positron emitter itself. 31 The mitochondria are composed of an outer membrane, intermembranous space, inner membrane, and matrix within ( Figure 2) . 30 In brief, 2 transporters carnitine palmitoyltransferase-1 and carnitine palmitoyltransferase-2 are necessary to transport acyl-CoA (end metabolite of cytosolic fatty acid metabolism) across the outer and inner membranes to the matrix where it undergoes β -oxidation to acetyl-CoA and in the process provides NADH (nicotinamide adenine dinucleotide) and FADH2 (flavin adenine dinucleotide 2; electron donors, hence the term reducing equivalents, with molecular O 2 as the electron acceptor) to the electron transport chain (ETC). A series of 4 distinct proton pumps (complexes I-IV) comprise the ETC. These pumps generate an electrochemical gradient (∆ψ ) across the inner membrane and in so doing make protons available to what has been termed complex V. 30 Complex V pumps the protons from the intermembranous space back to the matrix via a proton-sensitive ATP synthase, which phosphorylates ADP and so generates ATP, the life blood of the cell (Figure 2) . Pyruvate, the end metabolite of cytosolic glycolysis, is transported across the inner mitochondrial membrane by pyruvate dehydrogenase (PDH) where it joins the tricarboxylic acid (Krebs cycle) cycle as acetyl-CoA and in turn also contributes NADH and FADH2 to the ETC for ATP production. 30 Two important points to note about the process of ATP production are (1) under normal physiological conditions reactive oxygen species (ROS) are a natural byproduct and play a role in the normal functioning of the mitochondria 30 and (2) oxygen consumed in the process under a variety of pathological conditions may be uncoupled from ATP production and so not only is wasted but also contributes to the pathophysiology (eg, excess ROS generation 23, 26 ). In addition to carnitine palmitoyltransferase-2, PDH, the ETC, and complex V, the inner membrane has several other important regulatory components (Figures 1 and 2 ), in particular, the mPTP, cytochrome c (oxidase and reductase), as well as several important ion channels, including mK ATP (protein kinase C-ε activation and ROS generation), Na/K ATPase, Na/ Ca 2+ exchanger, Ca 2+ uniporter, Na/H + exchanger along with matrix MnSOD, and intermembranous Cu/ZnSOD. 26, 30 Each plays a role in maintenance of mitochondrial homeostasis and so ATP production. In the setting of acute ischemia/reperfusion potential interactions relevant to cell survival among these subsystems (Figure 1 ) are large in number and so only selected ones, especially important for imaging myocardial viability, will be considered.
mPTP and Mitochondrial Membrane Potential
The mPTP (Figure 1 ) has received considerable attention in the literature and is a key determinant of cell survival in the setting of acute ischemia/reperfusion. 23, 24, 26, 33 Opening of the pore, a large complex protein, may result in uncontrolled influx of ions and water with resultant mitochondrial swelling because of the high osmotic pressure of the matrix. These events may then be followed by collapse of ∆ψ and release of cytochrome c from intermembranous space into the cytoplasm with eventual rupture of the outer membrane. 23, 24, 26 Rupture of the cell membrane is followed by necrotic cell death or initiation of apoptotic cell death or both. 23 The mPTP initially is stabilized by reduced pH associated with ischemia, if not profound, but on reperfusion and resumption of ETC function, a burst of ROS is generated along with an increase in pH ( Figure 1 ) both of which destabilizes and opens the channel. 26 Interventions that use more gradual reperfusion, antioxidants, and maintain reduced pH have been shown to limit mPTP opening and promote cell survival. 23, 24 However, with more profound ischemia, ROS, as well as reactive nitrogen species release, is greater and results in irreversible opening of the mPTP and resultant cell death. 24 
mK ATP Channel and Mitochondrial Membrane Potential
The mK ATP channel is known to play a key role in cell survival mediated by ischemic pre-, post-, and remote conditioning. 24 The actual mechanism involved is not known in detail although ROS generation with subsequent protein kinase C-ε activation plays a role. 24 Opening of the channel also helps limit ischemia-induced flooding of Ca 2+ into the mitochondria and thereby stabilizes the mPTP. 23, 24, 26 Blockers of the channel, such as sulfonylurea drugs (eg, glibenclamide), abolish preconditioning effect on myocyte survival. In contrast, adenosine and other activators of the channel contribute to stabilization of mPTP and have been shown to play important roles in promoting survival. 23 Figure 1 ).
Myocyte Survival Mechanisms Operative in Chronic Stunning/Hibernation
Chronic myocardial stunning is best thought of as a transitional state in which repetitive episodes of myocardial ischemia (demand or reduced flow) are followed by persistent contractile and metabolic dysfunction, despite relief of the ischemic stimulus. [34] [35] [36] It has been shown that this state ultimately gives way to chronic, matched, reduction in MBF, and contractile function (ie, myocardial hibernation). [34] [35] [36] [37] It is known, however, during the transition that both chronic stunning and hibernation may coexist both in animal models [34] [35] [36] and in humans. 18 Furthermore, the hibernation state itself, notwithstanding a variety of adaptive mechanisms (Figure 3 ), may not persist indefinitely and ultimately may proceed to apoptotic or necrotic (or both) cell death with replacement of myocardium by fibrous scar.
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Metabolic Adaptation
Metabolic adaptations, which promote cell survival in chronically stunned/hibernating myocardium, primarily involve adjustments in myocyte fuel utilization. Thus, a key metabolic adaptation in mitochondrial ATP generation entails switch to glucose oxidative metabolism (Krebs cycle) in preference to but not exclusion of β-oxidation of fatty acid. 17, 40, 41 Although oxidation of glucose through the Krebs cycle is ≈13% more efficient than β-oxidation of fatty acid in terms of oxygen consumed per ATP generated (1 glucose yields 6.3 ATP/O 2 versus 5.6 ATP/O 2 for palmitate 42 ), the later generates considerably more ATP (38 versus 129; glucose versus palmitate, respectively 42 ) and so under normal conditions is the favored process although both participate and relative proportions vary with differing physiological and metabolic conditions. 41 Enhanced expression of the glucose transporter 1 transporter, which facilitates glucose entry into the cell, is a key switch in the fetal gene program for ATP generation. 43 It also underlies the classical PET observation of relative 18 FDG tracer uptake in excess of reduced rest MBF ( Figure 4 ) in viable, hibernating myocardium.
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Genetic Adaptations
There are several genetic programs initiated both in acute and in chronic ischemia, which are known to promote cell survival ( Figure 3 ). Whether the gene programs activated in response to acute low/no flow ischemia followed by reperfusion are the same as those initiated in response to transient demand-induced repetitive bouts of ischemia is not clear. What is widely agreed and understood is that a steady state of myocardial hibernation characterized by balanced reduced myocardial resting blood flow and contractile function may exist for a prolonged although not indefinite period of time 18, [37] [38] [39] 45, 46 and may be arrived at by repetitive stunning or by primary metabolic and ultimately genetic adaptation to sustained reduction in rest MBF. [34] [35] [36] 47 An initial ischemic stimulus may play a role as evidenced by previous animal work in short-term hibernation. 48, 49 A review of some of the more important genetic programs, often referred to as fetal in nature, is discussed below.
A large number of changes in gene expression have been reported in both human and animal models of chronic hibernation ( Figure 3) . 33, 43, 50 Most are thought to promote myocyte survival under conditions of frequent ischemic episodes. The mechanism of ischemia in some experiments seems to have been demand induced. 37, 46, 51 However, in one swine model, rest MBF was reduced 30% to 40% for 90 minutes, followed by reperfusion X 1 to 6, 12-hour cycles. 43 One hour after reperfusion, myocardium in remote and in stunned/ hibernating region was sampled for gene (polymerase chain reaction) and protein (Western) expression. The results of a parallel study in human subject (n=12) who had preoperative PET measurement of MBF ( 15 O-water) and myocardial biopsy obtained in hibernating and remote myocardium at the time of coronary artery bypass graft (CABG) surgery were compared with gene and protein expression data obtained in the swine model.
In humans, rest MBF in hibernating and remote myocardium did not differ significantly (0.91±0.05 mL·min ; mean±SD) in hibernating myocardium did not differ from that in remote (0.45±0.11 versus 0.43±0.05) notwithstanding upregulation and expression of glucose transporter 1. There were, however, significant differences in gene and associated protein expression between hibernating and remote zone. Thus, in hibernating myocardium "….antiapoptoic (IAP), growth (VEGF, H11 kinase), and cytoprotection (HSP 70, HIF-1α, glucose transporter 1)…." genes all were selectively upregulated with increased protein expression versus remote myocardium. 43 Accordingly, the authors concluded a "…an endogenous gene program of cell survival underlies the sustained viability of the hibernating heart." 43 Upregulation of inducible nitric oxide synthase (iNOS) and tumor necrosis factor-α (TNF-α) gene and protein expression in hibernating regions of hearts of human subjects also have been reported (Figure 3) . 52 Segments devoid of contractile reserve, which failed to improve post-CABG, were found to have the highest levels of iNOS and TNF-α gene expression whereas segments having contractile reserve, which improved contraction post-CABG, had intermediate levels in comparison with regions having normal contraction at baseline. It was hypothesized that intermediate levels of iNOS and TNF-α were helpful in maintaining myocardial viability by virtue of their negative inotropic effects and so were adaptive in a setting of chronically reduced rest and maximal MBF. 52 Both iNOS and TNF-α have potent mitochondrial effects as well; iNOS uncouples oxidative phosphorylation, thereby impairing ATP production while TNF-α induces expression of MnSOD, a potent antioxidant. 25 Thus, a dose-response relationship may have been present such that moderate levels of iNOS and TNFα expression permitted myocardial viability to be maintained in a hibernating state. 25 In contrast, more extreme expression of the same genes seems to favor cell death both apoptotic and necrotic. 25 Other gene programs that promote myocyte survival in hibernating myocardium target the mitochondria, as well as stress protein expression (Figure 3) . 50, 53 Thus, downregulation of mitochondrial proteins involved in oxidative metabolism, in particular PDH complex, acyl-CoA dehydrogenase, and ETC complexes I, III, and V (ATP synthase) has been reported. 50, 53 Survival promoting stress proteins, including GRP78, HSP27, HSP20-β6, and the antioxidant MnSOD all are upregulated. 50 Others have reported upregulation of H11-kinase and HSP70 in viable hibernating myocardium. 33 Regional findings in hibernating myocardium (genetic, metabolic, functional) may resemble those seen in models of chronic systolic left ventricular (LV) failure even though global LV systolic function may be normal and the hearts not dilated. 50 Moreover, the downregulation of mitochondrial enzymes involved at the entry point of oxidative metabolism (eg, PDH complex for pyruvate and acyl-CoA dehydrogenase for β-oxidation of fatty acids) in the hibernating region is indicative of an adaptive response to chronic low flow. 18, 37, 46, 54, 55 Upregulation of MnSOD has the potential to promote cell survival by limiting oxidant stress. 50 Furthermore, cytochrome c activity is reduced thereby potentially curtailing a potent trigger of apoptosis. 50 It is noteworthy the observed regional changes were maintained over at least 5 months and were not associated with increased fibrous tissue (versus remote) in the hibernating zone. 50 The findings are consistent with a steadystate adaptation to reduced MBF (rest and stress) which, over the period of time measured, did not exhibit evidence of infarction or progressive cell death. 37, 46, 50 These observations also are consistent with earlier work, which demonstrated myocardial adaption to sustained reduction in rest MBF, 37, 56 as well as the ability of such regions to tolerate an increase in myocardial oxygen demand and augment contraction (pacing with catecholamine stimulation) without showing metabolic evidence of ischemia 54 or progressing to infarction.
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Failure of Adaptive Mechanisms
Unfortunately, the adaptive mechanisms promoting myocyte survival and functioning discussed above ( Figure 3) tend to progress over longer periods of time, to myocyte death, albeit at variable rate and nonuniform fashion. Clinically, the result is heart failure with reduced LVEF 57, 58 and increased susceptibility to ventricular arrhythmia and sudden cardiac death. 59 Thus, there is evidence from human studies of hibernating myocardium 38, 39 that over a period of 6 or more months progressive myocyte loss occurs along with other structural derangements, such as disruption of cytoskeletal proteins titin and α-actinin 38 and replacement by fibrotic tissue. 38, 39 There also is evidence of increased myocardial glycogen content, loss of contractile elements, and changes in mitochondrial size and shape, all of which resemble what has been termed dedifferentiation to a fetal morphology. 38, 39, 43, 45 In this setting, activation of both myocardial and renal renin-angiotensin-aldosterone systems (RAAS) occurs and contributes to replacement of severely damaged myocytes with scar. 45, 60, 61 Conversion of angiotensin I to angiotensin II by angiotensin-converting enzyme (ACE) on the myocyte surface and chymase in the cytoplasm play important roles because angiotensin II promotes activation of collagen formation at the gene level ( Figure 5) . [61] [62] [63] [64] Molecular imaging of ACE has been shown to be feasible. 62 ACE imaging could serve as a useful tool for assessing not only extent of myocardial damage but also response to therapy directed at improving LV function in the setting of heart failure with reduced LVEF.
Knowledge Gaps-Determinants of Myocyte Survival
Perhaps the most important gap in our knowledge concerning myocyte survival in the setting of ischemia/reperfusion, as well as chronic stunning hibernation, relates to the absence of a coherent system integrating and ordering the interplay of the numerous mediators, which have been shown to play a role (Figures 1 and 3) . Thus, rapid restoration of pH, oxidative stress, intracellular calcium overload, opening of the mPTP, and inflammation all have been shown to be involved 27 ( Figure 1 ). Reperfusion injury related to microvascular obstruction also is a factor and if severe may result in intramyocardial hemorrhage. 65, 66 The relative importance of each of these factors and their interactions, however, are yet to be elucidated.
Moreover, it is apparent from histopathologic data obtained both from human subjects 38 and a swine model of hibernation 49 that (1) histopathologic severity of ischemic injury (mild versus severe) in humans does not correlate either with contractile impairment or its recovery on reperfusion with CABG 38 and (2) myofibrillar loss begins as early as 24 hours after acute stunning but is nonuniform in nature and progresses over a 2-week period both in the stenosis and normally perfused remote region of the same heart. 49 Myolysis begins before a rise in left ventricular end-diastolic pressure and in face of normal remote segment contraction. 49 Thus stretch, which may be a factor over the long term, does not seem required to initiate the process. Accordingly, it is reasonable to suggest that the seemingly stochastic nature of myocyte survival under conditions of ischemia/reperfusion exposes an important closely related gap in our knowledge; namely the mediators responsible for cell-to-cell differences in vulnerability to the same ischemic insult not only in the ischemic zone but territory remote from it. On a small, but still macro level scale (≈1 g or less), such variation may reflect fractal heterogeneity of both MBF and metabolism. 67, 68 At Figure 5 . the cellular level, mitochondrial heteroplasmy and the net of all variation in their inner membrane potentials may well confer considerable variability in vulnerability to ischemia/reperfusion injury (eg, more or less tolerance to decline and then restoration of pH as well burst of ROS on reperfusion; Figure 1) . A similar gap in our knowledge exists with respect to understanding the interrelationships among the vast number of factors involved in myocyte survival and contractile dysfunction in the setting of chronic stunning and hibernation, 33 which lies at one end of a continuum with acute ischemia/reperfusion on the other 34, 36, 47 ( Figure 3) . Thus, although a large number of response elements, both promoting cell survival and cell death, have been identified in the setting of chronic myocardial hibernation and stunning, integration of these many factors into a comprehensive understanding of the forces controlling progression from an adaptive genetic, metabolic, and morphological state of myocardial hibernation/stunning to one of cell death, both apoptotic and necrotic, even within the same local region of the heart, remain to be defined and are topics for future investigation. 33 Closing these gaps in our knowledge will be a complex and difficult process involving multiple disciplines 33 and even more time. At present, a better appreciation of how the entire system functions as a unified whole may be gained by computational modeling with newly reported neural network methodologies. [69] [70] [71] [72] [73] [74] On a cellular level, the ability to recognize individually resilient (or vulnerable) myocytes in principle may be facilitated by use of recently reported advances in immunotherapy of hematologic and solid tumor malignancies. 75 For example, β-integrin, a transmembrane surface protein known to be a stretch mechanoreceptor, has been associated with myocyte survival in humans with end-stage heart failure. 33, 76 It could be targeted with specific antibody labeled either with a PET isotope ( 11 C, 13 N, 18 F) or CMR nanoparticle and be used to identify cells which may be resistant to ischemia/reperfusion injury. Theoretically, activation of intracellular survival programs also seems possible by modification of the membrane spanning end of genetically engineered T-cell surface receptors, 75 which could be designed to recognize and treat instead of destroy various myocyte populations. Clearly, additional work is needed and only time will tell which approach(es) may be best. Nevertheless, progress to date provides information which will be useful for implementing new molecular imaging methodologies or improving existing ones for assessment of myocardial viability.
Interventions to Promote Myocyte Survival
Mechanical, Metabolic, and Pharmacological
Mechanical interventions to enhance myocyte survival in setting of acute ischemia/reperfusion have taken a variety of approaches. Thus, in an effort to prevent or mitigate the hazard of thrombus embolization associated with percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI) both thrombectomy aspiration catheters and distal protection devices have been used. The aspiration catheters seem to be superior to the distal protection devices in terms of clinical outcomes, 77 although both as demonstrated by CMR have met with variable success. Thus, distal embolization of clot remains a problem for myocyte survival and recovery of contractile function after PCI therapy for STEMI. 27, 77 It should be noted if a saphenous vein graft is the culprit vessel, then distal embolization of atherosclerotic debris including calcium and cholesterol emboli represent the predominant cause of microvascular obstruction associated with PCI therapy. Accordingly, in the setting of saphenous vein graft PCI, distal protection devices are more likely to be effective in limiting microvascular obstruction and dysfunction than antiplatelet, anticoagulant, and thrombectomy devices. [77] [78] [79] Efforts to replicate ischemic postconditioning and remote conditioning in humans with STEMI, as well as stable ischemic heart disease, also have been reported and have met with varying degrees of success. 23 Adenosine has been used in an effort to target the mK ATP channel and thereby mimic a key ischemic conditioning mechanism. Unfortunately, a large clinical trial using this intervention in patients with acute STEMI failed to demonstrate benefit with respect to primary clinical end point; death from any cause or heart failure. 80 Infarct size, however, tended to be smaller and clinical events fewer in a subset receiving the higher dose of adenosine. 80 A metabolic intervention designed to enhance glucose metabolism and reduce fatty acid oxidation by means of glucose-insulin-potassium infusion in patients with acute STEMI failed to demonstrate clinical benefit with respect to mortality, cardiogenic shock, and cardiac arrest. 81 Trimetazidine has been used in an effort to directly inhibit mitochondrial fatty acid oxidation and has shown some success as an antianginal agent and for treatment of heart failure 17 although use in the setting of acute ischemia/reperfusion has not been reported. Dichloroacetate targets the mitochondrial PDH complex by inhibiting PDH kinase, 17 thereby enhancing pyruvate entry into the mitochondria (Figures 1 and 2) . The net result is better linkage of glycolysis with glucose oxidation through the tricarboxylic acid (Krebs cycle) cycle 17 and so enhanced efficiency of ATP production under ischemic conditions. Dichloroacetate also has shown some benefit in improving LV systolic function in the setting of chronic ischemic heart disease 17 but has not been used under conditions of acute ischemia/reperfusion.
Imaging Targets for Clinical Myocardial Viability Assessment Microvascular Dysfunction
Coronary microvascular dysfunction may arise in either the setting of acute ischemia/reperfusion or the chronic stunning hibernation for a variety of reasons, some or all of which may be operative simultaneously. In humans, PCI directed at thrombus removal from the occluded coronary artery may be associated with distal embolization of clot fragments with resulting mechanical obstruction of distal medium and small caliber arteries and arterioles. If severe, reperfusion either may fail to occur (no reflow phenomenon) or result in intramyocardial hemorrhage because of loss of structural integrity of the microvasculature. Indeed, reperfusion hemorrhage has been demonstrated in a porcine model after as little as 15 minutes of sustained coronary occlusion followed by full reperfusion. 82 In clinical practice, typically involving much longer coronary occlusions (hours), reperfusion hemorrhage is uncommon and, as might be expected, is associated with severe microvascular obstruction and larger infarct size. 27, 66 In some cases, hemorrhage may be prevented if collaterals already are present or rapidly open after coronary occlusion. Then too, the culprit clot may have gone through several cycles of lysis and reformation before establishment of the thrombus observed at the time of STEMI presentation. Depending on number of cycles and precise timing both the microvasculature and the myocardium may have undergone natural preconditioning, which would then mitigate microvascular (and myocyte) damage and prevent or limit reperfusion hemorrhage. Additional mechanisms of microvascular dysfunction in the setting of acute ischemia/reperfusion include stunning, 83 which reflects ischemia-induced endothelial dysfunction related to ROS inhibition of endothelial nitric oxide synthase (eNOS) and degradation of nitric oxide itself. Calcium overload of endothelial cells represents another mechanism and can be inhibited by blockade of the Na + /H + exchange transporter. 27, 84 Vasoconstrictor substances such as endothelin released by thrombin and thromboxane A2 from platelets bound up with the clot also play a role. 77, 85 Thus, microvascular dysfunction reflects 2 components. One is anatomic because of physical obstruction by microemboli. Damage to microvessel endothelial lining and walls themselves also contributes. 66 The other is functional and reflects factors noted above related to endothelial cell dysfunction (ROS degradation of nitric oxide and eNOS inhibition) and presence of vasoconstrictor substances released either from the clot itself (thromboxane A2, thrombin) or from endothelial cells (endothelin).
In the setting of chronic stunning/hibernation, endothelial cell dysfunction is by far the predominant factor in impairing microvascular function and typically is exacerbated by comorbidities such as diabetes mellitus, hypertension, obesity, dyslipidemia, and previous infarction. 86 PET imaging may use any of the following tracers for absolute quantification of MBF;
13 N-ammonia, 82 Rb, or 15 O-water. 15, [87] [88] [89] [90] [91] PET measurement of absolute MBF, particularly the response to maximal vasodilator stress, is perhaps the most informative metric. It permits each coronary vascular territory (and subregions) to be evaluated independently of one another because reference is made to an absolute standard (eg, MBF response to adenosine in healthy controls). 15, 86, 89, 90, 92 In contrast, other methods typically use a relative, qualitative, or at best semiquantitative approach which assumes what seems to be the best perfused region of the myocardium is normal and hence free of microvascular dysfunction. In fact, neither conclusion may be warranted ( Figure 6 ). Indeed, in the setting of PCI for STEMI, microvascular dysfunction is known to be present notwithstanding full patency of the conduit vessel and may persist for weeks or longer after the acute event. 65, 93 Imaging coronary microvascular dysfunction also has been accomplished with other modalities, including contrast-enhanced echocardiography 94 and CMR with gadolinium contrast.
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Mitochondrial Membrane Potential
Measurement of the mitochondrial membrane potential may provide useful information concerning regional myocardial viability. Tetraphenylphosphonium (TPP) has been shown to distribute across the mitochondrial inner membrane in accordance with the Nernst potential and so has been used to measure ∆ψ. [95] [96] [97] [98] The compound more recently has been labeled with 18 F (4-18 F-TPP) 99 and thus can be imaged by PET to quantitatively determine the tracer concentrations required to solve the Nernst equation and, after correction for nonspecific binding, measure ∆ψ. 98, 100 In one such experiment employing 18 F-TPP with an isoflurane anesthetized, porcine model of acute myocardial ischemia/infarction, mitochondrial ∆ψ was found to be partially depolarized (ie, less negative) in the ischemic border zone (−66±17 mV) versus normal zone of the same animal (−82±13 mV; P<0.05). 100 Infarcted myocardium (MBF<0.05 mL·min
×>3 hours) had well counter computed ∆ψ (−37±4 mV) because of nonspecific 18 F-TPP binding and so was used as the correction factor for computing normal and border zone ∆ψ. The value of normal zone ∆ψ compared favorably (−100 mV) with that reported for Langendorff perfused, rat hearts working under conditions of increased myocardial oxygen demand, and with glucose added to the perfusate. 97, 98 Furthermore, the intact animals were under isoflurane anesthesia and had adenosine infusion during the imaging period. Both are known to open mK ATP and, as discussed above, partially depolarize the inner mitochondrial ∆ψ , 101, 102 which may well have contributed to rendering normal zone less negative than that for the Langendorff heart preparation (−100 mV) 28, 97, 98 and, as reviewed by others, less so far in vitro mitochondrial cell fractions (−150 to −180 mV). 28 There have been no reported human studies to date in which 18 F-TPP has been used to measure myocardial ∆ψ under any conditions. Nevertheless, the approach seems a promising one based on the results of the porcine study noted above and the large body of evidence indicating that the mitochondrial membrane potential plays a crucial role in cell survival in the setting of acute ischemia/reperfusion, as well as chronic stunning and hibernation. 28 
Delayed Enhanced CMR
CMR is presently one of the major imaging modalities for noninvasive assessment of myocardial viability. CMR assessment of myocardial viability relies primarily on regional contractile function and delayed gadolinium enhancement to determine extent of transmural scar (Figure 7) . [4] [5] [6] 19, 103 The earliest CMR observation of increased signal intensity (greater T1 shortening after contrast) in infarcted, nonviable myocardium (≈10 minutes after bolus injection of the contrast) was reported in 1993. 20 Reversibly injured (viable) myocardium did not exhibit increased contrast enhancement. The mechanism for the late gadolinium enhancement may relate to cellular degradation in the infarct region with an increase in tissue permeability and a consequent increase in the distribution volume of the extravascular space. When combined with the slow washout characteristic of gadolinium chelates from infarcted myocardium, the net result is delayed contrast-enhanced T1-weighted images that seem bright in the infarcted tissue. Because the contrast used is primarily an extracellular, interstitial agent, it has been hypothesized that it is the increased volume of distribution of the contrast molecules within the infarcted imaging voxel that is responsible for the greater shortening of the T1 relaxation time. 19, 20 Finally, CMR has proven useful in assessment of microvascular obstruction and intramyocardial hemorrhage each of which when present after PCI for STEMI has been associated with adverse prognosis. 5, 66 Beyond identifying areas of scarred myocardium in patients with CAD, increased myocardial fibrosis may also accompany pressure and volume overload of the LV, as well as infiltrative disease, such as sarcoidosis and amyloidosis in the absence of ischemia and cell death. 5 Although CMR patterns and imaging sequence are used to distinguish these entities from CAD scar, which typically runs from endo-to epicardium in a coronary artery distribution, the presence of increased fibrous collagen tissue may reflect part of the adaptive fetal phenotype in hibernation and so is not necessarily indicative of cell death. 35, 45, 50 The same is true of SPECT or PET imaging, which targets ACE 62, 63 and thus myocardial RAAS. The RAAS is active in promoting myocardial fibrosis by genetic mechanisms in which both angiotensin II and aldosterone play important roles ( Figure 5) . 60, 64, [104] [105] [106] Although fibrous tissue contributes to LV wall thickening and the pathophysiology of heart failure, for instance, by causing diastolic dysfunction, its presence per se is not necessarily indicative of cell death.
Glucose Metabolism
Metabolic adaptation to changes in regional MBF or other triggers is an essential component of maintaining cardiac function. PET imaging of myocardial 18 FDG, either fasting followed by oral glucose load or hyperinsulinemic-euglycemic clamp, targets the adaptive preference of the myocardium for glucose utilization under conditions of chronic hibernation and stunning (Figure 4) . 40, 107 In clinical practice, the classical sign of relative glucose utilization in excess of rest MBF (termed metabolism-perfusion mismatch) is the scintigraphic hallmark of viable, hibernating myocardium ( Figure 4 ) and portends excellent recovery of function after ). Reproduced with permission from Kajander et al. 90 Copyright © 2011, American Heart Association, Inc. Relationships between recovery of function after revascularization with contrast-enhanced cardiac magnetic resonance (CMR; A) and 2 thallium protocols optimized for viability detection: rest-redistribution (B) and stress-redistributionreinjection (C) imaging are shown. Irrespective of the imaging modality applied, the data suggest that recovery of function after revascularization is a continuum and is coupled to the ratio of viable to scarred myocardium within dysfunctional myocardial segments. The extent of infarct size on CMR or percent thallium defect on single photon emission tomography correlated with decreasing likelihood of functional recovery after revascularization. Reproduced with permission from Dilsizian. revascularization. 16 Other patterns (eg, mild balanced reduction of FDG and MBF and even reverse mismatch with rest MBF>FDG commonly, but not always, in the septal region with left bundle branch block) also have been taken as indicative of myocardial viability. 13, 108, 109 The converse, a match profound reduction of both MBF and FDG is indicative of scar that will not recover function after revascularization. 15, 110 Although one would think that quantitative measurement of FDG uptake (µmol·min
) would be superior to qualitative assessment, in practice it has proven not to be the case even in one human study in which the glucose transporter 1 transporter was shown to be upregulated. 43, 111 Accordingly, better targets are required particularly ones which exploit the quantitative capability of PET. Measurement of the absolute value of mitochondrial membrane potential is an excellent example and is in accord with a recent comprehensive review which emphasized the enduring need for quantitation (sic) in assessment of cardiac metabolism 17 and another which stressed the pivotal role of the mitochondrial membrane potential in ischemic heart failure.
28
Fatty Acid Metabolism and Myocardial Oxygen Consumption
11 C-palmitate (fatty acid metabolism) has been used extensively in experimental settings, both animals and humans, for assessment of myocardial fatty acid metabolism in a variety of clinical conditions, which are relevant to considerations of myocardial viability. 15, 17, [112] [113] [114] [115] [116] [117] [118] [119] [120] Myocardial ischemia per se also has been studied with the SPECT tracer ). 42, [123] [124] [125] [128] [129] [130] Although in theory both probes in conjunction with quantitative 18 FDG measurement of myocardial glucose metabolism could prove quite helpful in assessment of adaptive metabolic adjustment seen in viable hibernating myocardium, the requirements for (A) onsite cyclotron to make 11 C-labeled tracers; (B) 20 minutes half-life of 11 C-labeled tracer which therefore requires minimum 100 minutes wait between injections; (C) requirement for MBF measurement preferably with 13 N-ammonia (10 minutes half-life, with 50 minutes wait between injections; and (D) 2-hour half-life of 18 FDG (typical 1-hour dynamic data acquisition for quantitative study and 10-hour decay time), all mitigate against multitracer quantitative PET studies of cardiac metabolism to assess viability.
Nevertheless, studies using 18 FDG, typically combined either with or 82 Rb or 13 N-ammonia for assessment of MBF, are quite feasible and in many institutions are routinely used clinically for viability assessment (Figure 4 ). Recent data indicate when results of the FDG study are adhered to with respect to recommendation for CABG versus medical therapy for ischemic cardiomyopathy patients that outcomes may be improved by coronary revascularization. 13 18 FDG viability imaging will improve patient outcomes.
133
ETC Complex
ETC complex II has been shown to play a critical role in respiratory reserve capacity and myocyte survival under conditions of hypoxia. 134 Complex II is known to consist of succinate dehydrogenase which also is present in the tricarboxylic acid (Krebs cycle) cycle, and thus, it has been postulated that glucose metabolism is linked via pyruvate through the tricarboxylic acid (Krebs cycle) cycle to the ETC via complex II ( Figure 2 ) and so by turns promotes energy production under conditions such as hypoxia, and presumably ischemia, in which glucose utilization is favored over fatty acid oxidation. 134 Flurpiridaz is chemically related to the insecticide rotenone and is irreversibly bound to ETC complex I, 135 which is linked functionally to complex II (Figure 2 ). The compound has been labeled with 18 F and is under clinical development as a PET myocardial flow tracer. [135] [136] [137] [138] However, it seems clear that intact mitochondrial membrane structure and maintained, if not normal, ∆ψ is required for its retention by the myocardium. 135 Hence, it serves not only as an MBF tracer, but its linkage to ETC complex II (via complex I binding) suggests it may also serve as an indicator of myocardial viability especially under conditions of ischemia. It is possible an approach similar to that used for 18 F-TPP 100 also could be used to measure ∆ψ , although further research is required to test this hypothesis.
Renin-Angiotensin-Aldosterone System
The activation of the myocardial RAAS ( Figure 5 ), in response to chronically elevated loading conditions, commonly leads to a maladaptive cellular and molecular response that accompanies left ventricular remodeling. 64 An extensive left ventricular remodeling process may hamper or even prevent functional recovery of hibernating myocardium after revascularization in cardiomyopathy patients. 96, 139 In ischemic cardiomyopathy, it has been reported that the change in left ventricular ejection fraction after revascularization is linearly related to the baseline left ventricular end-systolic volume. 140 Higher left ventricular end-systolic volumes (mean 141±31 mL) were associated with a lower likelihood of improvement in left ventricular ejection fraction after revascularization even in the presence of significant hibernating myocardium. 140 In contrast, mean left ventricular end-systolic volume was significantly lower (109±46 mL) among patients with hibernating myocardium that exhibited improvement in their postoperative left ventricular ejection fraction.
The RAAS, an adept regulator of human physiology, is frequently activated early in heart failure and, through its primary effecter peptide angiotensin II, linked to left ventricular remodeling and myocardial fibrosis. Increased angiotensinconverting enzyme has been seen in association with myocardial fibrosis and inhibition of RAAS modulates left ventricular remodeling in heart failure. It is now known that the various components of RAAS are locally produced in the heart and that knowledge of the tissue expression of these enzymes and peptides could have important implications for the proper management of patients with heart failure. 141, 142 Radionuclide imaging of myocardial RAAS in a heart failure patient may offer a more direct, patient-specific, assessment of the RAAS activation. Such an approach has been used in experimental systems to study the human tissue angiotensin-converting enzyme and angiotensin type-1 receptor directly. [62] [63] [64] By use of the [ 18 F]fluorobenzyl-lisinopril in human explanted hearts, a relationship was observed between angiotensin-converting enzyme and collagen replacement, as angiotensin-converting enzyme was absent in the collagen-stained areas and was increased in the juxtaposed areas of replacement fibrosis. 63 These data suggest that increased angiotensin-converting enzyme may be a stimulus for collagen replacement and remodeling. A subsequent study with [ 99m Tc]lisinopril in human angiotensin-converting enzyme-1 overexpressing transgenic rats established the specificity of the radioisotope probe to myocardial angiotensin-converting enzyme-1 and demonstrated close correlation between the quantitative uptake of [ 99m Tc]lisinopril and the enzyme activity. 62 Moreover, the signal intensity was sufficiently high to allow external imaging by hybrid micro SPECT-computed tomography.
Recently, angiotensin type-1 receptor was also targeted for imaging the human heart. 143 This first-in-man application of receptor ligand [
11 C]-KR31173 combined with PET/ computed tomography confirmed the presence of local tissue RAAS in human hearts, proved to be safe, and showed that the signal was high enough to allow external imaging with PET. However, the myocardial retention of KR31173 was significantly lower in these healthy human subjects than those observed in normal healthy pigs with a limited specificity; only 54% of the signal targeted the angiotensin type-1 receptor. 61, 143 If reproduced in heart failure subjects, the in vivo application of these imaging techniques with either PET or SPECT would allow serial monitoring of angiotensin type-1 receptor or tissue angiotensin-converting enzyme activity in patients with heart failure and left ventricular remodeling.
Conclusions
Survival mechanisms operative in the setting of acute and chronic ischemia are substantial in number. 23, 24 Many are dose related such that the same mediators using the same or differing mechanisms may promote either cell survival or death, whether apoptotic or necrotic (or both). [23] [24] [25] 36 The importance of any given pathway and how it interacts with others understandably has been difficult to define given the multiplicity of vectors potentially involved (Figures 1 and 3) . What can be said is that the mitochondria seem to be the final common target of the great majority both in acute ischemia/reperfusion with its varied forms of conditioning regimes and in chronic hibernation/stunning. [23] [24] [25] 36 In chronic stunning/hibernation, a metastable state is arrived at characterized by reduced rest blood flow, metabolism, and contraction. A large number of genes have been reported to be up-or I-iodophenyl-pentadecanoic acid; CMR, cardiac magnetic resonance; CT, computed tomography; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; PET, positron emission tomography; and SPECT, single photon emission tomography.
